PH asa sa tira ng mayayamang bansa : 80% suplay ng COVID bakuna pinakyaw

Nabili ng mayayamang bansa ang malaking bahagi ng global supply COVID-19 vaccine ayon kay vaccine czar, Secretary Carlito Galvez.

The post PH asa sa tira ng mayayamang bansa : 80% suplay ng COVID bakuna pinakyaw first appeared on Abante.

ph asa sa tira ng mayayamang bansa 80 suplay ng covid bakuna pinakyaw - PH asa sa tira ng mayayamang bansa : 80% suplay ng COVID bakuna pinakyaw
abante galves 3 - PH asa sa tira ng mayayamang bansa : 80% suplay ng COVID bakuna pinakyaw

Nabili ng mayayamang bansa ang malaking bahagi ng global supply COVID-19 vaccine ayon kay vaccine czar, Secretary Carlito Galvez.

“The reality is that more than 80% of global supply has already been procured by rich countries,” pahayag ni Galvez sa pagdinig ng Senate Committee of the Whole kahapon.

Ayon sa kalihim, patuloy naman ang pakikipagnegosasyon nila sa iba’t ibang pharmaceutical company para makabili ng COVID-19 vaccine supply.

“We, along with other countries, are now trying our best to negotiate with different vaccine companies to get a fair share of the vaccines for the remaining 18% of the global supply,” sabi ni Galvez.

Muling iginiit ni Galvez na target ng bansa na bakunahan ang 50 hanggang 70 milyong Pinoy laban sa coronavirus disease.

Nakikipagnegosasyon din aniya sila pito hanggang walong drug manufacturer para bumili ng hanggang 140 milyong doses.

“But because of the restrictions on the supply chain… we might be having some sort of shortfall maybe on the second or first quarter of 2022,” sambit pa nito.

Kasabay nito ay inihayag ni Galvez na malaking bahagi ng COVID-19 vaccine na gagamitin ng Pilipinas ay gawa ng US drug maker Novavax.

“Our main volumes will be coming from Novavax with 30 to 40 million doses,” ani Galvez.

Ang Novavax COVID-19 vaccine na pinangalang, Covovax, ay gagawin ng Serum Institute of India (SII). (Dindo Matining)

The post PH asa sa tira ng mayayamang bansa : 80% suplay ng COVID bakuna pinakyaw first appeared on Abante.

Leave a Reply

Your email address will not be published. Required fields are marked *